Literature DB >> 18521344

Absence of telomerase activity in malignant bone tumors and soft-tissue sarcomas.

Nina K Lauer1, Sandra M Maier, Martin Oberringer, Michael Schulte, Wolf Mutschler, Rainer G Hanselmann, Manfred Schartl, Stefan J Scherer, Reiner J Wirbel.   

Abstract

PURPOSE: Telomerase activity appears to play a crucial role in the development of many tumors. More than 80% of all malignant human tumors show an increased telomerase activity. However, conflicting results have been reported about telomerase activity in sarcomas. The aim of the study was to obtain more information about telomerase activity in sarcomas based on a large number of cases.
METHODS: Telomerase activity was measured in 69 different tumor samples (33 malignant bone tumors and 36 soft tissue sarcomas). Tumor samples were obtained intraoperatively and frozen immediately in liquid nitrogen. Telomerase activity was detected by the telomeric repeat amplification assay (TRAP-assay).
RESULTS: Only 7% of the samples showed telomerase activity. No correlation between staging and telomerase activity could be observed. DISCUSSION: The fact that only five out of 69 examined tumor samples showed a telomerase activity provides experimental evidence that in sarcomas the reactivation of telomerase may play a subordinate role. Our results suggest that alternative mechanisms for cell immortalization, yet to be determined, seem to be involved in the development and/or maintenance of soft-tissue sarcomas and malignant bone tumors.

Entities:  

Year:  2002        PMID: 18521344      PMCID: PMC2395492          DOI: 10.1080/13577140220127549

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  15 in total

1.  Expression of telomerase activity and telomerase RNA in human soft tissue sarcomas.

Authors:  J Yoo; R A Robinson
Journal:  Arch Pathol Lab Med       Date:  2000-03       Impact factor: 5.534

Review 2.  Immortalized cells with no detectable telomerase activity. A review.

Authors:  R R Reddel; T M Bryan; J P Murnane
Journal:  Biochemistry (Mosc)       Date:  1997-11       Impact factor: 2.487

Review 3.  Life and cancer without telomerase.

Authors:  V A Zakian
Journal:  Cell       Date:  1997-10-03       Impact factor: 41.582

Review 4.  Telomere maintenance without telomerase.

Authors:  H Biessmann; J M Mason
Journal:  Chromosoma       Date:  1997-07       Impact factor: 4.316

5.  Defects in mismatch repair promote telomerase-independent proliferation.

Authors:  A Rizki; V Lundblad
Journal:  Nature       Date:  2001-06-07       Impact factor: 49.962

Review 6.  Telomere dynamics and telomerase activity in in vitro immortalised human cells.

Authors:  T M Bryan; R R Reddel
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

7.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines.

Authors:  T M Bryan; A Englezou; L Dalla-Pozza; M A Dunham; R R Reddel
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

8.  Telomerase activity in skeletal sarcomas.

Authors:  G Aue; B Muralidhar; H S Schwartz; M G Butler
Journal:  Ann Surg Oncol       Date:  1998 Oct-Nov       Impact factor: 5.344

9.  On telomere shortening in soft-tissue tumors.

Authors:  R Schneider-Stock; C Epplen; K Radig; Y Oda; H Dralle; C Hoang-Vu; J T Epplen; A Roessner
Journal:  J Cancer Res Clin Oncol       Date:  1998       Impact factor: 4.553

10.  Telomere elongation in immortal human cells without detectable telomerase activity.

Authors:  T M Bryan; A Englezou; J Gupta; S Bacchetti; R R Reddel
Journal:  EMBO J       Date:  1995-09-01       Impact factor: 11.598

View more
  2 in total

Review 1.  Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.

Authors:  Jixuan Gao; Hilda A Pickett
Journal:  Nat Rev Cancer       Date:  2022-07-05       Impact factor: 69.800

Review 2.  Telomere maintenance in soft tissue sarcomas.

Authors:  Nicholas Eastley; Barbara Ottolini; Carmen Garrido; Jacqueline A Shaw; Thomas Alasdair McCulloch; Robert U Ashford; Nicola J Royle
Journal:  J Clin Pathol       Date:  2017-02-09       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.